According to one embodiment, a method includes contacting a triiodobenzoic acid with an oxalyl chloride in a solvent whereby triiodobenzoyl chloride is formed, contacting diethanolamine with triiodobenzoyl chloride where triiodobenzoic diol amine is formed, and forming an acrylate of triiodobenzoic diol amine with acryloyl chloride where an organoiodine compound is formed. According to another embodiment, an optically clear photopolymer resist blend for additive manufacturing includes a radiopaque pre-polymer compound where the compound includes at least one of the following: iodine, bromine, tin, lead, or bismuth. The resist blend also includes a photoinitiator, a polymerization inhibitor, and a base pre-polymer.

According to one embodiment, a method includes contacting a triiodobenzoic acid with an oxalyl chloride in a solvent whereby triiodobenzoyl chloride is formed, contacting diethanolamine with triiodobenzoyl chloride where triiodobenzoic diol amine is formed, and forming an acrylate of triiodobenzoic diol amine with acryloyl chloride where an organoiodine compound is formed. According to another embodiment, an optically clear photopolymer resist blend for additive manufacturing includes a radiopaque pre-polymer compound where the compound includes at least one of the following: iodine, bromine, tin, lead, or bismuth. The resist blend also includes a photoinitiator, a polymerization inhibitor, and a base pre-polymer.

The present invention discloses 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(-hydroxypentyl)benzoic acid potassium salt.

The present invention discloses 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(-hydroxypentyl)benzoic acid potassium salt.

Disclosed are methods for synthesizing an ester or a carboxylic acid from an organic alcohol. To form the ester one reacts, in the presence of oxygen gas, the alcohol with methanol or ethanol. This reaction occurs in the presence of a catalyst comprising palladium and a co-catalyst comprising bismuth, tellurium, lead, cerium, titanium, zinc and/or niobium (most preferably at least bismuth and tellurium). Alternatively that catalyst can be used to generate an acid from that alcohol, when water is also added to the reaction mix.

Disclosed are methods for synthesizing an ester or a carboxylic acid from an organic alcohol. To form the ester one reacts, in the presence of oxygen gas, the alcohol with methanol or ethanol. This reaction occurs in the presence of a catalyst comprising palladium and a co-catalyst comprising bismuth, tellurium, lead, cerium, titanium, zinc and/or niobium (most preferably at least bismuth and tellurium). Alternatively that catalyst can be used to generate an acid from that alcohol, when water is also added to the reaction mix.

The present invention discloses 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(-hydroxypentyl)benzoic acid potassium salt.

The present invention discloses 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(-hydroxypentyl)benzoic acid potassium salt.

A metal complex is disclosed. In an embodiment the metal complex includes at least one metal atom M and at least one ligand L attached to the metal atom M, wherein the ligand L has the following structure:

##STR00001##

wherein E.sup.1 and E.sup.2 are oxygen, wherein the substituent R.sup.1 is selected from the group consisting of branched or unbranched, fluorinated aliphatic hydrocarbons with 1 to 10 C atoms, wherein n=1 to 5, wherein the substituent R.sup.2 is selected from the group consisting of CN, branched or unbranched aliphatic hydrocarbons with 1 to 10 C atoms, aryl and heteroaryl, and wherein m=0 to at most 5n.

This document discloses molecules having the following formula (Formula One):

##STR00001##

and processes associated therewith.